Malignant Gastric Neoplasm — Trials

Malignant Gastric Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

2,842 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 652
Recruiting: 351
Ph III recruiting: 49
Growth YoY: +15.1%
Industry share: 26%
Top sponsor: Fudan University
Termination share: 26.2%
Trials / 1,000 deaths: 59.5 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (232)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02065765	International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer	approved for marketing	—	—	Eli Lilly and CompanyINDUSTRY	5	Jan 9, 2025	clinicaltrials
NCT02307812	Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France	approved for marketing	—	—	Eli Lilly and CompanyINDUSTRY	0	Jan 9, 2025